Congo Approves Clinical Trials for Novel Oral Ebola Treatment
Kinshasa, Monday, 13 July 2026.
As Ebola spreads in Congo, NanoViricides secured approval for Phase II trials of NV-387, a novel treatment uniquely formulated as oral gummies to simplify epidemic response.
Phase II Trial Approvals Amid Expanding Outbreak
Today, July 13, 2026, clinical-stage biopharmaceutical firm NanoViricides, Inc. (NYSE American: NNVC) announced it has secured National Ethics Committee approval in the Democratic Republic of the Congo (DRC) to launch a Phase II clinical trial for its lead candidate, NV-387 [1]. This clinical trial will evaluate the efficacy of NV-387, formulated uniquely as oral gummies, as a treatment for the Bundibugyo Ebolavirus [1]. To proceed, the company is currently preparing to file a Clinical Trial Application (CTA) with the ACOREP regulatory agency in the DRC [1]. This regulatory milestone is particularly timely as the DRC faces an escalating Ebola outbreak that recently expanded into two new provinces, Haut-Uele and Tshopo, as of July 12, 2026 [1].
A Growing Epidemic and the Need for Scalable Solutions
The urgency of finding scalable therapeutic interventions is highlighted by the scale of the current outbreak. On May 17, 2026, the World Health Organization (WHO) declared the current Ebola outbreak a Public Health Emergency of International Concern (PHEIC) [1]. As of July 12, 2026, official data recorded 1,926 confirmed cases and 702 deaths [1]. Using these figures, the case fatality rate currently stands at approximately 36.449 percent [1]. Worryingly, epidemiological models from the Centers for Disease Control and Prevention (CDC) project that the outbreak could balloon to between 10,000 and 20,000 cases, resulting in 2,000 to 4,000 deaths within the next three months if containment measures are not optimized [1].
Operational Advantages and the Pipeline Strategy
From a logistical standpoint, NanoViricides has a unique operational advantage in the DRC. The physical supplies of NV-387 required for the clinical trial are already present in the country, having been previously shipped for a separate Phase II clinical trial targeting Mpox [1]. This pre-existing supply chain reduces the immediate shipping hurdles during an active epidemic [1]. In addition to its Ebola and Mpox programs, the clinical-stage biopharmaceutical firm is developing NV-387 for various respiratory viral infections, including influenza, RSV, and coronaviruses [1][2]. The drug previously received US FDA Orphan Drug Designation for Mpox treatment in February 2026 [2].
Financial Realities and Investor Considerations
Navigating the lengthy and capital-intensive drug development process poses substantial financial challenges for the micro-cap biotech firm. As of July 12, 2026, NanoViricides reported a market capitalization of $34.70 million, with 22,982,817 shares outstanding [3]. Over the preceding 12-month period, the company’s stock price fluctuated between a low of $0.85 and a high of $2.23 [3]. While the company maintains that its current funding is sufficient to execute the planned Phase II Mpox trial, future clinical operations and the expansion of the Ebola trial remain contingent on securing additional capital [2]. This dependency introduces liquidity risks and the potential for future shareholder dilution [2]. Indeed, the company reported a 32.23% increase in shares outstanding over the 12 months preceding July 12, 2026, alongside capital expenditures of approximately $94,516 [2].